Akorn, Inc. has signed an exclusive development and supply agreement with Sofgen Pharmaceuticals to develop and commercialize an ANDA drug product. Under the agreement, Sofgen is responsible for the formulation and development of the drug, the manufacture of clinical product batches, and the documentation to support the Chemistry, Manufacturing and Control (CMC) section of an ANDA, which will be filed by Akorn. Upon approval, Sofgen will supply finished dosage form product to Akorn. Akorn will b...